SynAct Pharma – executive interview

In this interview, we speak with Mads Bjerregaard, chief business officer of SynAct Pharma, following the release of top-line results from the Phase IIb ADVANCE study of resomelagon in rheumatoid arthritis. He discusses the key takeaways from the results, which did not achieve statistical significance on the primary DAS28-CRP endpoint but demonstrated encouraging efficacy signals, including an ACR20 response rate of 76.4% at the selected 40mg dose and significant efficacy in the ACR/EULAR Class II-III subgroup. Mads also highlights the significance of the biomarker and safety findings, the implications for SynAct’s differentiated pro-resolution approach and the potential impact on regulatory interactions, Phase III planning and partnering discussions. Finally, he discusses potential read-throughs for the ongoing RESPIRE study and the key milestones investors should watch over the next 12 months.

SynAct Pharma (STO: SYNACT) is a clinical-stage biotechnology company developing first-in-class therapies that promote inflammation resolution without suppressing the immune system. Its lead asset, resomelagon, is an oral melanocortin agonist being developed for rheumatoid arthritis and acute inflammatory conditions. Following the recent Phase IIb ADVANCE readout, the company’s focus is on regulatory engagement, Phase III planning and advancing the broader inflammation-resolution platform, including the ongoing Phase II RESPIRE study.